Cite
HARVARD Citation
Clément, K. et al. (2020). Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet. 8 (12), pp. 960-970. [Online].